Despite the partial success of anti-PD-1–chemotherapy combinations in first-line advanced GC, 40%–50% of patients still do not respond and median OS improvements remain modest (about 2–3 months), highlighting the urgent need for effective biomarkers to guide patient selection, with PD-L1 CPS being more predictive than TPS. This evidence concerns the gene PDCD1 and gastric cancer.